Whilst further studies are still required to investigate the mechanism that mediates these beneficial effects, our findings provide new insights toward the development of albumin, either alone or in conjunction with other therapeutic approaches, to reduce hepatic steatosis. This evidence concerns the gene ALB and fatty liver disease.